Zhou Xia-Qing, Li Ya-Ping, Dang Shuang-Suo
Department of Infectious Diseases, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China.
World J Hepatol. 2024 Feb 27;16(2):164-176. doi: 10.4254/wjh.v16.i2.164.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and poses a major challenge to global health due to its high morbidity and mortality. Conventional chemotherapy is usually targeted to patients with intermediate to advanced stages, but it is often ineffective and suffers from problems such as multidrug resistance, rapid drug clearance, nonspecific targeting, high side effects, and low drug accumulation in tumor cells. In response to these limitations, recent advances in nanoparticle-mediated targeted drug delivery technologies have emerged as breakthrough approaches for the treatment of HCC. This review focuses on recent advances in nanoparticle-based targeted drug delivery systems, with special attention to various receptors overexpressed on HCC cells. These receptors are key to enhancing the specificity and efficacy of nanoparticle delivery and represent a new paradigm for actively targeting and combating HCC. We comprehensively summarize the current understanding of these receptors, their role in nanoparticle targeting, and the impact of such targeted therapies on HCC. By gaining a deeper understanding of the receptor-mediated mechanisms of these innovative therapies, more effective and precise treatment of HCC can be achieved.
肝细胞癌（HCC）是最常见的原发性肝癌，因其高发病率和死亡率对全球健康构成重大挑战。传统化疗通常针对中晚期患者，但往往无效，且存在多药耐药、药物快速清除、非特异性靶向、副作用大以及肿瘤细胞中药物蓄积低等问题。针对这些局限性，纳米颗粒介导的靶向给药技术的最新进展已成为治疗HCC的突破性方法。本综述重点关注基于纳米颗粒的靶向给药系统的最新进展，特别关注HCC细胞上过度表达的各种受体。这些受体是提高纳米颗粒递送特异性和疗效的关键，代表了主动靶向和对抗HCC的新范例。我们全面总结了目前对这些受体的认识、它们在纳米颗粒靶向中的作用以及此类靶向治疗对HCC的影响。通过更深入地了解这些创新疗法的受体介导机制，可以实现对HCC更有效、精确的治疗。
